NEW METHOD TO ACTIVATE STREPTOMYCES SECONDARY METABOLISM CRYPTIC PATHWAYS
The aim of the StrepCrypPath is to test the industrial potential of a new approach to enhance Streptomyces secondary metabolism, discovered in our ERC-StG Strp-differentiation (280304) project. We discovered a pleiotropic regulato...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto StrepCryptPath
Duración del proyecto: 27 meses
Fecha Inicio: 2019-01-17
Fecha Fin: 2021-04-30
Líder del proyecto
Universidad de Oviedo
No se ha especificado una descripción o un objeto social para esta compañía.
Total investigadores790
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The aim of the StrepCrypPath is to test the industrial potential of a new approach to enhance Streptomyces secondary metabolism, discovered in our ERC-StG Strp-differentiation (280304) project. We discovered a pleiotropic regulator of differentiation and secondary metabolism in the S. coelicolor model strain. The S. coelicolor strain lacking this regulator is the first Streptomyces reported to produce secondary metabolites during its whole developmental cycle, including germination, the exponential growth phase and the stationary stage. S. coelicolor encodes 30 secondary metabolites, but only two are produced in high amounts under the culture conditions used in our lab. The expression of 15 secondary metabolite clusters (50% of the total), including 6 predicted to participate in secondary metabolite biosynthesis never observed in the lab (cryptic pathways), is activated/enhanced, in our mutant.
The gene encoding this new regulator is highly conserved in Streptomyces. We will explore if the inactivation of the orthologues of this regulatory gene in industrial streptomycetes causes the same phenotype observed in S. coelicolor: secondary metabolism and cryptic pathway activation. We will create integrative conjugative plasmids harbouring antisense mRNAs to inactivate this gene. We do not expect that this method will enhance and/or activate all secondary metabolite clusters. However, if as it happens in S. coelicolor, we can activate/enhance 50% of the secondary metabolite pathways, including several cryptic pathways, in any streptomycete, we can revolutionise the screening for new secondary metabolites from streptomycetes.